NovaBridge Biosciences (NBP) Tax Provisions (2020)
NovaBridge Biosciences (NBP) posted quarterly Tax Provisions of -$8.2 million for Q4 2024, down 344.31% quarter-over-quarter from -$1.8 million in Q4 2020.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Tax Provisions (2020) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Tax Provisions for 2 consecutive years, with -$8.2 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Tax Provisions changed N/A year-over-year to -$8.2 million; the TTM figure through Sep 2025 stood at -$10.0 million (changed N/A YoY), while the FY2024 annual figure was -$8.2 million, up 39.55% from the prior year.
- Tax Provisions slipped to -$8.2 million in Q4 2024 per NBP's latest filing, from -$1.8 million in the prior quarter.
- Across five years, Tax Provisions topped out at -$1.8 million in Q4 2020 and bottomed at -$8.2 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.90 Mn |
| 10 | NovaBridge Biosciences | 199.88 Mn | 199.88 Mn | - | - |